Predicting pathology on small bowel capsule endoscopy: a good FIT

Current clinical practice lacks reliable non-invasive tools to predict small bowel pathology before capsule endoscopy. While capsule endoscopy is valuable for diagnosing suspected small bowel bleeding, its use is not always guided by pre-procedural biomarkers. Prior research has shown that fecal immunochemical tests [FIT] detect occult blood with high specificity. However, it was unclear if FIT could predict small bowel pathology. This gap motivated a study to evaluate FIT as a potential predictor. No prior work had resolved whether FIT could serve as a triage tool for capsule endoscopy. Existing knowledge suggested FIT's role in colorectal cancer screening but not in small bowel diagnostics. This paper's contribution is to explore FIT's utility in this new context. The study aimed to determine if FIT could improve patient selection for capsule endoscopy. By addressing this question, the research may help optimize diagnostic workflows.

The study aimed to assess whether fecal immunochemical test [FIT] results could predict the likelihood of finding pathology during small bowel capsule endoscopy [SBCE]. The specific problem addressed was the lack of a non-invasive biomarker to guide SBCE referrals. Patients with suspected small bowel bleeding or anemia were the focus. The motivation was to improve diagnostic efficiency and reduce unnecessary procedures. The research sought to determine if FIT could serve as a screening tool. It also examined whether combining FIT with anemia status improved predictive accuracy. The goal was to provide a practical tool for clinical triage. This approach could help clinicians decide which patients need SBCE.

The study used a prospective cohort design with patients referred for SBCE. Inclusion criteria required prior negative upper and lower endoscopy results. FIT positivity was defined as ≥45 ug Hb/g. SBCE was considered positive if a potential source of bleeding was identified. The primary endpoint was the correlation between FIT and SBCE findings. Secondary endpoints included anemia status and a combination of anemia and FIT. Statistical analysis included odds ratios and confidence intervals. The sample size was 51 patients, with outcomes measured in percentages and probabilities.

Among 51 patients, 29.4% had a positive FIT, and 25.5% had significant SBCE findings. A statistically significant association was found between positive FIT and SBCE pathology (OR 12, 95% CI 2.8–51.9, p=0.001). FIT had 69% sensitivity and 84% specificity in predicting SBCE findings. Normal hemoglobin levels had an 83% negative predictive value (NPV). Combining FIT and anemia status improved prediction (OR 9.14, 67% PPV, 82% NPV, p=0.025). These results suggest FIT is a useful biomarker. The combination of FIT and anemia further enhances predictive accuracy. These findings support FIT's role in guiding SBCE referrals.

The authors propose that FIT ≥45 ug Hb/g is a useful predictor of small bowel pathology on SBCE. The study suggests FIT alone or in combination with anemia status can aid in patient triage. This approach may help clinicians prioritize SBCE referrals. The findings support FIT as a screening tool in this context. The combination of FIT and hemoglobin improves diagnostic accuracy. These results suggest a practical application in clinical practice. The study does not claim FIT is essential but highlights its value. The authors suggest further validation in larger cohorts.